The combination of a DNMT inhibitor with a PARP inhibitor impaired the BRCA‐mediated DDR and sensitized PARP inhibitor‐resistant ovarian cancer to PARP inhibitor therapy regardless of BRCA status.75 Here, PARP1 is linked to ovarian cancer.